Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2006

View Archived Issues

Oregovomab under investigation in epithelial ovarian cancer

Inolimomab treatment in pediatric graft-versus-host disease reviewed

Nabi licenses ATG-Fresenius S for U.S. and Canada

Valera acquires rights to Valstar

Vaxon-Biotech and Institut Pasteur collaborate on cancer immunotherapy

Enrollment open in first pivotal study of cangrelor

Scynexis and Xsira design new selective GRK-2 inhibitors

Potent FXR antagonists from Amgen

Amazon Biotech preparing HIV studies for AMZ-0026

Bionomics receives Australian grant to advance vascular disruption agent

Innate Pharma and Novo Nordisk partner on drugs targeting natural killer cells

Phase III study of Efaproxyn cleared to continue

CytRx completes enrollment in phase IIa study of arimoclomol for ALS

QLT and Retinagenix sign agreement in retinal diseases

Cordis to establish global cardiac and vascular institute

OncoMethylome to participate in phase III study of temozolomide

Amorfix obtains rights to additional novel SOD1 targets

New phase II study evaluates OT-551 in geographic atrophy

Enrollment completed in phase I study of Provacel in heart attack patients

Viral Therapeutics changes name to Vybion

Duramed withdraws Lo Seasonale NDA

Roche presents novel and selective GlyT1 inhibitor as a candidate for schizophrenia

Unibioscreen develops novel lactosylated steroids with antimigratory activity against cancer cells

Wyeth selects potent Src kinase inhibitor from new series

PARP inhibitor simultaneously enhances antitumor activity and reduces neuropathy of cisplatin

Recent patents cover therapeutic agents for neurological disorders

New analgesic agents reported in recent patent literature

Novel tachykinin NK1 antagonists prepared and tested by Takeda

Novel potent fibrate analogues synthesized at Dr. Reddy's